MYGN Stock - Myriad Genetics, Inc.
Unlock GoAI Insights for MYGN
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $837.60M | $753.20M | $678.40M | $690.60M | $557.00M |
| Gross Profit | $585.40M | $517.00M | $476.40M | $493.00M | $378.80M |
| Gross Margin | 69.9% | 68.6% | 70.2% | 71.4% | 68.0% |
| Operating Income | $-123,500,000 | $-257,400,000 | $-140,600,000 | $-190,500,000 | $-194,800,000 |
| Net Income | $-127,300,000 | $-263,300,000 | $-112,000,000 | $-27,200,000 | $-223,700,000 |
| Net Margin | -15.2% | -35.0% | -16.5% | -3.9% | -40.2% |
| EPS | $-1.41 | $-3.18 | $-1.39 | $-0.35 | $-2.99 |
Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing the risks for hereditary cancers; BRACAnalysis CDx Germline Companion Diagnostic Test, a DNA sequencing test to help determine the therapy for patients with metastatic breast, ovarian, metastatic pancreatic, or metastatic prostate cancer with deleterious or suspected deleterious germline BRCA variants; and MyChoice CDx Companion Diagnostic Test, a tumor test that determines homologous recombination deficiency status in patients with ovarian cancer. The company also offers Prolaris Prostate Cancer Prognostic Test, a RNA expression tumor analysis for assessing the aggressiveness of prostate cancer; EndoPredict Breast Cancer Prognostic Test, a RNA expression test for assessing the aggressiveness of breast cancer; Precise Tumor, a solution for precision oncology; and Prequel Prenatal Screen, a non-invasive prenatal screening test conducted using maternal blood to screen for severe chromosomal disorders in a fetus. In addition, it provides Foresight Carrier Screen, a prenatal test for future parents to assess their risk of passing on a recessive genetic condition to their offspring; and GeneSight Psychotropic Mental Health Medication Test, a DNA genotyping test to aid psychotropic drug selection for patients suffering from depression, anxiety, ADHD, and other mental health conditions. Myriad Genetics, Inc. has a strategic collaboration with Illumina, Inc. and Intermountain Precision Genomics for an offering of germline and somatic tumor testing services. The company was founded in 1991 and is headquartered in Salt Lake City, Utah.
Visit WebsiteRating Distribution
Price Targets
Recent Analyst Actions
| Date | Firm | Action | Rating | Price Target |
|---|---|---|---|---|
| May 21st 2025 | Scotiabank | Downgrade | Sector Perform | $6 |
| May 8th 2025 | Wolfe Research | Downgrade | Peer Perform | - |
| May 7th 2025 | Wells Fargo | Downgrade | Equal Weight | $6 |
| April 9th 2025 | Guggenheim | Downgrade | Neutral | - |
| March 12th 2025 | Piper Sandler | Upgrade | Overweight | $12.5← $11.5 |
| February 12th 2025 | Craig Hallum | Initiation | Buy | $29 |
| December 10th 2024 | UBS | Initiation | Neutral | $18 |
| December 9th 2024 | Leerink Partners | Downgrade | Market Perform | $21← $30 |
| September 19th 2024 | Morgan Stanley | Initiation | Equal Weight | $32 |
| August 28th 2024 | Wells Fargo | Initiation | Overweight | $35 |
| June 27th 2024 | Scotiabank | Initiation | Sector Outperform | $29 |
| June 3rd 2024 | Jefferies | Resumed | Underperform | $20 |
| May 8th 2024 | Leerink Partners | Upgrade | Outperform | $35← $25 |
| December 21st 2023 | Piper Sandler | Resumed | Neutral | $23 |
| December 19th 2023 | Wells Fargo | Initiation | Equal Weight | $20 |
Earnings History & Surprises
MYGNEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Feb 23, 2026 | $-0.02 | — | — | — |
Q4 2025 | Nov 3, 2025 | $-0.01 | $-0.13 | -1200.0% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-0.01 | $0.05 | +600.0% | ✓ BEAT |
Q2 2025 | May 6, 2025 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q1 2025 | Feb 24, 2025 | $0.03 | $0.03 | 0.0% | = MET |
Q4 2024 | Nov 7, 2024 | $0.02 | $0.06 | +215.8% | ✓ BEAT |
Q3 2024 | Aug 6, 2024 | $0.01 | $0.05 | +509.0% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-0.11 | $-0.01 | +90.9% | ✓ BEAT |
Q1 2024 | Feb 27, 2024 | $0.01 | $0.04 | +214.2% | ✓ BEAT |
Q4 2023 | Nov 6, 2023 | $-0.08 | $-0.03 | +62.5% | ✓ BEAT |
Q3 2023 | Aug 3, 2023 | $-0.10 | $-0.08 | +20.0% | ✓ BEAT |
Q2 2023 | May 3, 2023 | $-0.19 | $-0.21 | -10.5% | ✗ MISS |
Q1 2023 | Feb 28, 2023 | $-0.16 | $-0.12 | +25.0% | ✓ BEAT |
Q4 2022 | Nov 1, 2022 | $-0.06 | $-0.19 | -216.7% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $0.01 | $0.04 | +300.0% | ✓ BEAT |
Q2 2022 | May 5, 2022 | $-0.05 | $-0.03 | +40.0% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-0.02 | $-0.02 | -14.3% | ✗ MISS |
Q4 2021 | Nov 2, 2021 | $0.01 | $-0.02 | -300.0% | ✗ MISS |
Q3 2021 | Aug 3, 2021 | $-0.07 | $0.12 | +271.4% | ✓ BEAT |
Q2 2021 | May 3, 2021 | $-0.10 | $-0.06 | +40.0% | ✓ BEAT |
Latest News
Piper Sandler Maintains Overweight on Myriad Genetics, Lowers Price Target to $8.5
➖ NeutralMyriad Genetics Adds 15 Additional Genes Into MyRisk Hereditary Cancer Test Germline Testing
📈 PositiveMyriad Genetics To Present 11 New Research Data In Oncology, Reproductive Genetic Testing At National Society Of Genetic Counselors
📈 PositiveWells Fargo Maintains Equal-Weight on Myriad Genetics, Raises Price Target to $6.5
➖ NeutralTD Cowen Maintains Hold on Myriad Genetics, Raises Price Target to $9
➖ NeutralUBS Maintains Neutral on Myriad Genetics, Raises Price Target to $8
➖ NeutralMyriad Genetics shares are trading lower after the company issued Q3 financial results and issued FY25 adjusted EPS guidance below estimates.
📉 NegativeMyriad Genetics Affirms FY2025 Adj EPS Guidance of $(0.02)-$0.02 vs $0.01 Est; Affirms FY2025 Sales Guidance of $818.000M-$828.000M vs $821.658M Est
➖ NeutralMyriad Genetics Q3 Sales $205.700M Beat $204.897M Estimate
📈 PositiveMyriad Genetics Announces Post-Hoc Analysis Of PRIME Study Showing Treatment Informed By GeneSight Test Led To Faster Initial Remission And Response In Patients With MDD
📈 PositiveMyriad Genetics And SOPHiA GENETICS Collaborate To Develop And Provide Pharmaceutical Companies With Innovative Global Liquid Biopsy Companion Diagnostic Test
📈 PositiveReported Earlier, Myriad Genetics Announces Precise MRD Study Findings Showing ctDNA As Predictive Biomarker For Response To Metastasis-Directed Radiotherapy In ccRCC
📈 PositiveMyriad Genetics Publishes Meta-Analysis Of 3,532 MDD Patients Showing GeneSight Psychotropic Test Improves Response And Remission Rates Vs. Standard Treatment
📈 PositiveANGLE Partners With Myriad Genetics To Explore Extension Of Tissue-Based Companion Diagnostic Tests To Blood-Based CTC-DNA Testing
📈 PositiveMyriad genetics announces new $200 million credit facility
📈 PositiveFrequently Asked Questions about MYGN
What is MYGN's current stock price?
What is the analyst price target for MYGN?
What sector is Myriad Genetics, Inc. in?
What is MYGN's market cap?
Does MYGN pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to MYGN for comparison